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Demyelination in the central nervous system induced by neurovirulent strains of
Mouse Hepatitis Virus (MHV) is mediated by the viral spike glycoprotein, but it is
not clear whether the mechanism of this disease pathology involves direct viral
infection of oligodendrocytes. Detailed studies of glial cell tropism of MHV are
presented, demonstrating that direct MHV infection of oligodendrocytes differs between
demyelinating (RSA59) and non-demyelinating (RSMHV2) viral strains both in vitro and
in vivo. Our results indicate that direct injury of mature oligodendrocytes is an important
mechanism of virus-induced demyelination. In vivo, RSA59 infection was identified in
spinal cord gray and white matter, but infected oligodendrocytes were restricted to white
matter. In contrast, RSMHV2 infection was restricted to gray matter neurons and was not
localized to oligodendrocytes. In vitro, RSA59 can infect both oligodendrocyte precursors
and differentiated oligodendrocytes, whereas RSMHV2 can infect oligodendrocyte
precursors but not differentiated oligodendrocytes. Viral spreading through axonal means
to white matter and release of the demyelinating strain MHV at the nerve end is
critical for oligodendrocytes infection and subsequent demyelination. Understanding the
mechanisms by which known viruses effect demyelination in this animal model has
important therapeutic implications in the treatment of human demyelinating disease.
Keywords: oligodendrocytes, astrocytes, mouse hepatitis virus, virus host attachment spike protein,
demyelination, multiple sclerosis
INTRODUCTION
Demyelination is the process by which axons lose their normal insulating myelin. Multiple
sclerosis (MS) is a chronic, progressive, or relapsing and remitting demyelinating disorder that
affects the central nervous system (CNS) specifically. In addition to demyelination, there is
partial loss of oligodendroglial cells and axonal degeneration predominately within white matter,
although some demyelination in MS also involves gray matter (Sharma et al., 2001; Bo et al.,
2003; Vercellino et al., 2005; Lassmann et al., 2007; Rudick and Trapp, 2009). The mechanism
of demyelination in MS is unknown, but may involve a T cell response triggered by virus
infection (Allen and Brankin, 1993; Hernán et al., 2001; Hemmer et al., 2002). Despite numerous
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attempts to identify an etiologic agent, a specific virus
has not been recognized. Various animal models have
been developed to study MS, including experimental
autoimmune encephalomyelitis (Kornek et al., 2000) as
well as viral-induced CNS demyelinating disease models.
One particularly useful mouse model utilizes MHV-induced
demyelination that mimics the pathology of MS (Das Sarma,
2010).
Previous studies in our laboratory have analyzed
the pathogenesis of recombinant MHV strains, RSA59
(demyelinating strain; DM), and RSMHV2 (non-demyelinating
strain; NDM) that are isogenic except for the spike gene
that encodes the virus-host attachment glycoprotein (Das
Sarma et al., 2000, 2008, 2009). Both strains are capable
of causing hepatitis, encephalitis, and meningitis, however,
the two strains differ in their ability to induce subsequent
demyelination and axonal loss (Das Sarma et al., 2009). Seven
days post-infection, RSA59 produces demyelination that is
best observed in the spinal cord. In contrast, RSMHV2 does
not produce demyelination and only rarely demonstrates
axonopathic changes in spinal cord white matter (Das Sarma
et al., 2009). The inability of RSMHV2 to induce demyelination
is due in part to a lack of transport of viral antigen (and
the subsequent inflammatory reaction) to the white matter.
Furthermore, in vivo and in vitro experiments demonstrate
deficits in the ability of RSMHV2 to spread between neurons
when compared to inter-neuronal spread by RSA59 (Das Sarma
et al., 2009). RSA59-induced demyelination occurs in the setting
of both axonal degeneration as well as macrophage mediated
myelin stripping along intact axons (Das Sarma et al., 2009).
While spike glycoprotein mediates spread of viral antigen to
white matter through axonal transport, specific mechanisms
leading to subsequent demyelination are not known. Viral
antigen in white matter axons may be sufficient to trigger an
inflammatory response that damages myelin. Alternatively, viral
antigen may need to spread directly into oligodendrocytes, or
indirectly to oligodendrocytes via astrocytes, using the spike
protein.
Previously, another demyelinating strain, MHV-JHM, has
been shown to produce a rapidly fatal encephalomyelitis,
although some temperature sensitive mutants can produce
non-fatal demyelination due to selective destruction of
oligodendrocytes (Dubois-Dalcq et al., 1982). RSA59 or
its parental demyelinating strain MHV-A59 can infect
oligodendrocytes in vitro, isolated from either rat or mouse,
or in oligodendrocyte cell lines (Liu et al., 2006, 2011; Li
et al., 2010). Nevertheless, the inability of the RSMHV2
strain to induce demyelination has not been resolved and
may be due to an inability to selectively destroy/impair
oligodendrocytes in the spinal cord white matter. Alternatively,
the failure of RSMHV2 to effect demyelination may be
related to impaired axonal transport as has already been
observed (Das Sarma et al., 2009). In the current study,
viral tropism of RSA59 and RSMHV2 in spinal cord
oligodendrocytes, myelin, neurons, and astrocytes is compared
in order to further clarify the mechanism(s) of viral-mediated
demyelination.
MATERIALS AND METHODS
Ethics Statement
Use of animals and all experimental procedures were reviewed
and approved by the Institutional Animal Care and Use
Committee at the Philadelphia College of Osteopathic Medicine
and Indian Institute of Science Education and Research-Kolkata
(IISER-K). Animal protocols adhered to the guidelines of the
United States National Institutes of Health Office of Laboratory
Animal Welfare Guide for the Care and Use of Laboratory
Animals, 8th Edition as well as CPCSEA, India.
Viruses
Recombinant isogenic demyelinating (DM) strain of MHV,
RSA59, and non-demyelinating (NDM) strain RSMHV2 were
described in our previous studies (Das Sarma et al., 2002, 2008).
RSA59 and RSMHV2 are isogenic except for the spike gene,
which encodes an envelope glycoprotein that mediates many
biological properties of MHV including viral attachment to
host cells, as well as virus-cell and cell-cell fusion (Gallagher
and Buchmeier, 2001). These recombinant strains also express
enhanced green fluorescence protein (EGFP) (Das Sarma et al.,
2002).
Inoculation of Mice
Four-week-old, MHV-free, C57BL/6 (B6) mice (Jackson
Laboratories, Bar Harbor, Maine) were inoculated intracranially
with 50% LD50 dose of RSA59 strain (20,000 PFU) or RSMHV2
(100 PFU) as described previously (Das Sarma et al., 2002, 2008).
Ten mice were infected in each group.
Briefly, viruses were diluted in phosphate-buffered saline
(PBS) containing 0.75% bovine serum albumin. Mice were
anesthetized with 100mg/kg ketamine and 10mg/kg xylazine
prior to inoculation. For intracerebral (i.c.) injection, 25ml of
diluted virus was injected directly through the skull into the
left cerebral hemisphere. Mock-infected controls were injected
similarly with an uninfected L2 cell lysate at a similar dilution.
Mice were monitored daily for potential signs of disease
including weight loss, waddling gait, partial limp, or lack of
appetite. As with our prior studies, all mice developed minimal
or no signs of disease, and mice were therefore sacrificed at
time points based on the known disease course from prior
histologic studies (Das Sarma et al., 2002, 2008). At the time
of sacrifice, mice were anesthesized with ketamine/xylazine,
then perfused transcardially with PBS, followed by cold PBS
containing 4% paraformaldehyde and finally with 10ml of
PBS containing 10% sucrose. Spinal cord and brain tissues
were removed and placed at 4◦C for 4 h in 10% sucrose,
followed by 30% sucrose overnight. Tissues were embedded in
OCT medium (Tissue Tek, Hatfield, PA), sectioned sagitally
with a microtome to 6µm thickness, and mounted on glass
slides.
Five mice were sacrificed at day 6 post-infection for viral titer
estimation as well as routine paraffin based histopathological
analysis and the rest were used for frozen sections. Cervical,
thoracic and lumbar regions of spinal cord were harvested
from each of 4 RSA59-infected and 5 RSMHV2-infected mice 6
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days after inoculation. Four quadrants (dorsal/posterior column,
anterior column, and two anterior horns) from two separate
sections of each spinal cord level were examined. All together,
we examined 96 quadrants for RSA59 and 120 quadrants for
RSMHV2.
Immunofluorescence Microscopy
Immunofluorescence was performed on cryosections harvested
from cervical, thoracic and lumbar regions of spinal cord from
each of 4 RSA59-infected and 5 RSMHV2-infected mice 6 days
after inoculation as described). For Olig2 staining, a Tyramide
signal amplification kit (Molecular Probes CAT# T-20935;
Invitrogen; Eugene, Oregon) was used. Primary antibodies
and their dilutions to detect specific CNS cell types are
listed in Table 1. Control slides were incubated in parallel
with pre-immune rabbit sera, and sections from mock-infected
mice were incubated with secondary antibodies only. Tissue
sections were sequentially washed with PBS plus Triton X-
100 and with PBS, then mounted and visualized by the Leica
TCS SPE Confocal system. We examined 4 quadrants (dorsal
column, ventral column, and two ventral horns) from two
separate sections of each spinal cord level. All together we
examined 96 quadrants for RSA59 and 120 quadrants for
RSMHV2.
For Olig2 staining, sections were specially post-fixed with ice-
cold 95% ETOH at −20◦C for 20min. These were subsequently
washed with 1X ice-cold TBS (Tris Buffer Saline) at room
temperature (RT) for 10min. Post-fixed tissues were processed
as previously described (Das Sarma et al., 2008) for washing,
permeabilization, and blocking prior to the addition of the
anti-Olig2 antibody. Biotinylated anti-Rabbit IgG was used as
secondary antibody and sections were incubated for 30min at
RT. Further staining steps were followed as per the Tyramide
signal amplification kit manual. Briefly, sections were washed
with 1X blocking buffer (10mg/ml Component D) for 15min and
labeled with Strep-HRP (provided with the kit; 1:200 dilutions in
diluted component D) at RT for 30min with three consecutive
1X TBS washes for 5min each. Sections were then stained with
Tyramide (1:200 dilution in amplification buffer) for 10min at
RT, washed three times with 1X TBS for 5min each and then
mounted in Vectashield (Vector laboratories Inc; Burlingame,
CA) with DAPI.
To determine the colocalization of RSA59 viral antigen
to axonal cytoskeletal structures, sections were incubated for
2 h with monoclonal primary antibodies anti-TAU, anti-MAP
(2A + B), anti-Neurofilament (NFM) and anti-Synaptophysin
(Syn) to label the axonal microtubules, dendritic microtubules,
axonal Neurofilament and synaptic terminals, respectively.
Primary antibody incubation was followed by incubation with
TRITC conjugated secondary goat anti-Mouse IgG for 1 h. All
incubations were performed at 37◦C in humidified chambers.
Sections were mounted in Vectashield with DAPI.
All images were obtained with an Olympus IX81 fluorescence
microscope. Images were acquired using Image ProPlus software
with a 40X objective and Hamamatsu monochrome cool charged
couple device camera. Images were taken in green and red
excitation filters for EGFP and TRITC, respectively for each
region and then merged with the help of the software.
TABLE 1 | List of antibodies and their dilutions used for immunofluorescence.
Target cell/structure Primary antibody Primary antibody dilution Fluorescent conjugated
secondary antibody
Secondary antibody dilution
Oligodendrocytes Olig2, Rabbit Polyclonal anti-Olig2
antibody (Millipore Corporation,
Billerica, MA)
1:500 Biotinylated Goat anti-Rabbit IgG
(Jackson Immunoresearch, West
Grove, PA)
1:100
Astrocytes Rabbit polyclonal Anti-Glial Fibrillary
Acidic Protein antibody (DAKO,
Carpinteria, CA)
1:100 CY3-Goat anti-Rabbit IgG (Jackson
Immunoresearch, West Grove, PA)
1:100
Myelin sheath PLP (Proteo lipid protein) Rat IgG (Gift
from Judith B. Grinspan, Children’s
Hospital of Philadelphia, Philadelphia,
PA)
1:1 Texas Red-Goat anti- Rat IgG
(Jackson Immunoresearch, West
Grove, PA)
1:100
Axonal microtubule Mouse monoclonal anti-Tau antibody
(Sigma,)
1:100 TRITC-goat-anti-mouse IgG
(Jackson Immunoresearch)
1:100
Dendritic microtubule Mouse monoclonal anti-MAP2(2a +
2b) antibody (Sigma,)
1:100 TRITC-goat-anti-mouse IgG
(Jackson Immunoresearch,)
1:100
Neurofilament Mouse monoclonal, Mouse
monoclonal anti-NFM (Neurofilament)
antibody (Sigma)
1:100 TRITC-goat-anti-mouse IgG
(Jackson Immunoresearch)
1:100
Synaptophysin Mouse monoclonal 1:50 TRITC-goat-anti-mouse IgG
(Jackson Immunoresearch)
1:100
Oligodendrocyte
precursor cells
Mouse monoclonal anti-A2B5
antibody (Ref 21)
Neat Rhodamine goat anti-mouse IgM
(Jackson Immunoresearch)
1:100
Matured and differentiated
oligodendrocytes
Mouse monoclonal anti-GalC
galactocerebroside) antibody(Ref 21)
1:2 Rhodamine goat anti-mouse IgM
(Jackson Immunoresearch)
1:100
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Isolation of Oligodendrocyte-Precursor
Cells (OPCs) from Neonatal Mouse Brain
Primary cultures of mixed glial culture were prepared from day 0
newborn mice (Barres et al., 1992; Grinspan and Franceschini,
1995; Marek et al., 2008). Briefly, following the removal of
meninges, brain tissues were minced and incubated in a shaking
water bath at 37◦C for 30min in Hanks Balanced Solution
(HBBS, GIBCO Life Technologies; Eugene, Oregon) in the
presence of 300µg/ml DNaseI and 0.25% trypsin (Sigma; St.
Louis, MO). Enzyme digested dissociated cells were triturated
with 0.25% fetal bovine serum (FBS), followed by a wash and
centrifugation (300 × g for 10min). The pellet was resuspended
in HBBS, passed through a 70µm nylon mesh, followed by a
second wash and centrifugation (300 × g for 10min). Following
dilution with initial plating medium (Dulbecco’s essential
medium containing 1% penicillin-streptomycin, 0.2mM L-
glutamine and 10% FBS), cells were plated and allowed to adhere
for 1 day in a humidified CO2 incubator at 37
◦C. After 24 h,
any non-adherent cells were removed with HBBS without Ca
and Mg and cells were switched to a serum free growth medium
{Neurobasal medium containing B27 and 10 ng/ml and bFGF
(Gibco Life Technologies,Eugene, Oregon) 2 ng/ml PDGF, and
1 ng/ml NT-3(PeproTech Inc. Rocky Hill, New Jersey}. Cultures
were maintained in this medium until confluent (approximately
1 week). Oligodendrocyte progenitor cells (OPCs) present in
mixed glial culture (mainly astrocytes and OPCs) were subjected
to dislodging by a wash down method taking advantage of the
differential adhesion properties of OPCs and astrocytes. OPCs
mainly grow on top of the astrocyte layer and are less adherent
than astrocytes. Dislodged oligodendrocytes were plated onto
Poly-D-Lysine coated coverslips and maintained in serum free
growth medium until the culture reached 80% confluence.
Adherent cells were trypsinized and plated onto glass coverslips
for cellular characterization.
Oligodendrocytes and Type-II astrocytes separated as
described above were plated to determine viability and ability to
grow in culture. In culture, they both grew well and exhibited the
expected morphology. Purity of the culture was established using
double label immunofluorescence with anti-GFAP and anti-
A2B5 antibodies (markers for OPCs) as well as counterstaining
with DAPI to detect cross contamination of GFAP-positive
cells in OPC cultures and A2B5-positive cells in Type –II
astrocyte cultures. Cultures were also stained with anti-CD11b
antibody (microglia/macrophage marker) to look for microglia
contamination, and routinely no CD11b positive cells were
observed (data not shown).
Differentiation of Oligodendrocytes
Confluent OPCs were maintained in Oligodendrocyte
Differentiation Medium {DMEM: F12 (1:1), 10% FBS
supplemented with Transferrin (10 ug/ml), Insulin (5µg/ml)
and Sodium Selenite (30 nM) for 7–10 days. Day 7
differentiated oligodendrocyte cultures were stained with
anti-GalC (Galactocerebroside), a marker of differentiated
oligodendrocytes. Negative CD11b staining confirmed
differentiated cultures remained free of microglia.
Infection of Primary OPCs and
Differentiated Oligodendrocytes (DOs) with
RSA59 and RSMHV2
On day 7 after explantation, OPCs or differentiated
oligodendrocyte cultures were infected at a multiplicity of
infection (MOI) of 1 with RSA59 and RSMHV2 or mock infected
with non-infected cell lysate. After allowing viral adsorption for
1 h, cells were washed and placed in fresh specifiedmedia without
virus. At 24 h after infection, cultures were immunolabeled with
either anti A2B5 or anti-GalC. Details concerning antibodies and
dilutions are shown in Table 1.
Quantification of Infected
Oligodendrocytes In vivo and In vitro by
RSA59 and RSMHV2
Quantification of viral strain infectivity in vivo was determined
by examination of 10 random spinal cord sections in which
one hundred olig2 positive cells were counted by a blinded
investigator. The percentage of virally infected olig2 positive
cells in RSA59 and RSMHV2 infection was calculated. A similar
strategy was used to quantify strain specific infection of PLP
positive oligodendrocytes. In vitro quantification of strain specific
infection of OPCs was determined by counting one hundred
OPCs in 10 separate random tissue culture dish microscopic
fields (20X). Statistical comparisons between the percentage
of oligodendrocytes (OPCs or DOs) infected by RSA59 vs.
RSMHV2 were made using unpaired two tailed student t-tests,
with p ≤ 0.05 considered statistically significant.
RESULTS
RSA59 (DM) and RSMHV2 (NDM) Differ in
Their Selective Tropism for
Oligodendrocytes in Gray and White Matter
In order to elucidate the mechanism(s) of selective tropism of
the RSA59 (DM) and RSMHV2 (NDM) strains, it is necessary
to identify the types and distribution of cells within the CNS
capable of supporting viral infection and transport. Four-
week-old, MHV-free, C57BL/6 (B6) mice (Jackson Laboratory)
were inoculated intracranially with either RSA59 or RSMHV2.
MHV replication reaches its peak at day 5, and inflammation
reaches its peak at day 7 post-infection. At day 5 post-
infection, viral antigen from the RSA59 strain is localized to
the spinal cord gray matter with subsequent spread to the
adjacent white matter. At day 7 following RSA59 infection,
viral antigen is mainly localized to the white matter (Das
Sarma et al., 2008). In contrast, while at day 5 post-infection,
the RSMHV2 strain viral antigen is transported to the spinal
cord from the brain, viral replication and spread is primarily
confined within the gray matter even at day 7 post-infection
with infrequent spread to the white matter. Based upon the
viral antigen dissemination kinetics, imaging was performed
on spinal cord cryosections from day 6 post-infection when
viral spread is maximal while cellular damage is limited.
Since the viral strains used express EGFP, virus-infected cells
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FIGURE 1 | Localization of RSA59 virus-infected cells and Olig2 in the spinal cord of infected mice at day 6 p.i. Spinal cord dorsal columns were derived
from mice infected with RSA59. A representative image showing EGFP fluorescence indicative of viral infection (green; A), and Olig2 labeling (red; B) does not
demonstrate co-localization of EGFP and Olig2 in the merged image (C). Dorsal columns white matter (D) and ventral horn white matter (E) reveal Olig2 positive nuclei
surrounded by EGFP positive cytoplasm (arrows). Rare examples of co-localization are observed in (D, arrowhead). No co-localization or Olig2 positive nuclei
surrounded by EGFP positive cytoplasm was observed in the gray matter (F). (A–C, 100X; D–F, 630X).
FIGURE 2 | Localization of RSMHV2 virus-infected cells and Olig2 in the spinal cord of mice at day 6 p.i. EGFP fluorescence (green; A) indicating viral
infection is restricted to spinal cord gray matter whereas Olig2 labeling (red; B) is present in both gray and white matter at day 6 p.i. Merged images are shown in
(C,F), while dorsal columns are outlined in white. Higher magnification images demonstrate a lack of co-localization of EGFP and Olig2 (D–F). Arrows mark Olig2
positive nuclei in which there is an inhomogeneous distribution of Olig2. (A–C, 100X; D–F, 630X).
were viewed directly by fluorescence microscopy. Identification
of oligodendrocytes was performed using anti-sera to Olig2
(transcription factor for oligodendrocytes), usually present in
oligodendrocyte nuclei. Detection was performed utilizing a red
fluorescent Cy3-conjugated secondary antibody.
EGFP fluorescence of spinal cord sections from RSA59
infected mice demonstrates infection of both gray (ventral
horns) and white matter (dorsal and ventral columns). Olig2
staining observed in gray and white matter oligodendrocytes is
primarily nuclear, whereas EGFP fluorescence is restricted to
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FIGURE 3 | Infection of oligodendrocyte precursors with RSA59 and RSMHV2. Glial cells were isolated from neonatal C57Bl/6 mice and cultured in chemically
defined medium specific for oligodendrocytes or oligodendrocyte precursors (OPCs). Seven day old mock infected mixed glial cells or cultures enriched for
oligodendrocyte precursors or OPCs were double immunostained with anti A2B5 antibody, a marker for oligodendrocyte precursors (red) and anti GFAP, a Type-II
astrocytic marker (green); nuclei were counterstained with DAPI (blue). Mixed glial culture (A) demonstrates labeling for both cell markers; cultures enriched for
oligodendrocyte precursors or OPCs stain positive for TYPE-II astrocytes (B) or OPCs (C), respectively. Three sets of mixed glial cultures enriched for OPCs were
infected with RSA59 (D–F) or RSMHV2 (G–I) at a MOI of 1. Virus-infected cells were identified by EGFP (green). EGFP expression in A2B5 positive cells shows that
RSA59 can infect OPCs and form syncytia that is characteristic of infection by the demyelinating MHV strain (D–F). In RSMHV2-infected cultures, several cells were
double positive for A2B5 (red) and EGFP (green), however, no syncytia were observed in RSMHV2-infected oligodendrocyte precursors (G–I). Magnification (A–I:
600X). Arrows mark double positive cells.
the cytoplasm (Figures 1A–C). Higher magnification images of
the dorsal column white matter (Figure 1D, upper portion with
inset) and gray/white matter junction (Figure 1E with inset)
demonstrate red Olig2 nuclear fluorescence surrounded by EGFP
cytoplasmic green fluorescence. These cells represent infected
oligodendrocytes. Double fluorescence/immunofluorescence
staining of the gray matter (Figure 1F) does not show Olig2
nuclear/EGFP cytoplasmic staining.
Similar staining was performed on spinal cord sections from
RSMHV2 infected mice (Figure 2). Viral infection was restricted
to the gray matter whereas Olig2 stained cells were observed in
both gray and white matter. However, there were no examples
of Olig2 nuclear/EGFP cytoplasmic fluorescence of cells in either
gray or white matter as was observed in the white matter of
RSA59 infected mice.
RSA59 strain is not only more efficient in producing
widespread infection of gray and white matter; it also
demonstrates increased localization to oligodendrocytes.
Quantification of Olig2 immunofluorescence and EGFP revealed
that 50% of Olig2 positive oligodendrocytes were infected by the
RSA59 strain in the spinal cord white matter (see Quantification
of Infected Oligodendrocytes in vivo and in vitro by RSA59 and
RSMHV2 Section). For the purposes of this analysis, the dorsal
columns and adjacent spinal cord gray matter were chosen since
they were consistently identifiable at each level of the cord and
showed the clearest and sharpest demarcation between gray and
white matter.
RSA59 and RSMHV2 Differ in Their Ability
to Infect Oligodendrocyte Precursors
(OPCs) and Differentiated
Oligodendrocytes (DOs) In vitro
We next examined the ability of the two MHV strains
to infect isolated oligodendrocyte precursors as well as
differentiated matured oligodendrocytes in vitro. Double
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 December 2015 | Volume 9 | Article 488
Kenyon et al. Mouse Hepatitis Virus Induced Gliopathy
FIGURE 4 | RSA59 and RSMHV2 differ in their ability to infect differentiated mature oligodendrocytes. Confluent oligodendrocyte precursor enriched
cultures were maintained in oligodendrocyte differentiated medium for 7 days and infected with RSA59 or RSMHV2 at a M.O.I. of 1 for 24 h. Virus-infected cells were
identified by EGFP (green). Differentiated oligodendrocytes were stained with anti-GalC antibody (marker for differentiated oligodendrocytes, red). Sister cultures of
differentiated oligodendrocytes were either mock infected (A–C) or infected with RSA59 (D–F), or with RSMHV2 (G,H). In all three RSA59 infected cultures (D–F)
syncytia formation is obvious and there are drastic reductions in the expression of GalC, but in RSMHV2 infected cultures, most of the infected cells were not
oligodendrocytes. These data suggest that RSA59 can infect differentiated oligodendrocytes whereas RSMHV2 is unable to infect differentiated oligodendrocytes.
Magnification (A–H: 600X). Thick arrows mark differentiated matured oligodendrocytes in (A–C). Thin arrows in (D–F) mark infected mature oligodrndrocytes which
formed syncitia. Arrowheads in (G,H) mark the differentiated oligodendrocytes which are not infected by RSMHV2.
label immunofluorescence with A2B5 (for OPCs) and GFAP (for
astroctyes) or GalC (differentiated matured oligodendrocytes)
confirmed that 60–70% of the cells either in oligodendrocyte
precursor cultures or oligodendrocyte differentiated cultures
were positive for A2B5 or GalC, respectively. Oligodendrocyte
precursors were readily infected with both RSA59 and
RSMHV2 whereas differentiated oligodendrocytes were only
infected by RSA59. In both precursor cells and differentiated
oligodendrocytes, RSA59 forms syncytia. In contrast, RSMHV2
infected cells were unable to form syncytia. In both cases,
viral infection is associated with a dramatic reduction in GalC
expression. This is the first demonstration that RSA59 and
RSMHV2 strains have differential oligodendroglial tropism both
in vitro and in vivo (Figures 3, 4).
Both RSA59 and RSMHV2 are Unable to
Infect Astrocytes in the Spinal Cord
Despite the facility by which the two MHV stains infect
oligodendrocyte precursors in vitro, they are unable to infect
spinal cord astrocytes in vivo. Immunofluorescence for
GFAP, a specific marker of glial cells, especially astrocytes,
was present throughout the spinal cord gray and white
matter in RSA59 and RSMHV2 infected mice, however
double fluorescence/immunofluorescence staining failed
to demonstrate co-localization of virus and astrocytes
(Figure 5).
RSA59 but not RSMHV2 Can Spread to the
Myelin Sheath
Infection of oligodendrocyte cell bodies does not necessarily
assure viral antigen spread into the myelin sheath. Therefore,
we performed double fluorescence/immunofluorescence staining
of the dorsal columns utilizing EGFP expression by infected
cells and proteolipid protein (PLP), a protein associated with
CNS myelin (Figure 6). PLP fluorescence is observed in
both RSA59 and RSMHV2 infected mice. In RSA59 infected
mice, the EGFP signal is predominately in an axonal pattern
with surrounding PLP fluorescence. However, there is some
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FIGURE 5 | EGFP expression in RSA59 or RSMHV2 infected cells does not co-localize with astrocytes in the spinal cord. Mice were infected with either
RSA59 (A–C) or RSMHV2 (D–F). EGFP fluorescence (green; A,D) identifies virus infected cells whereas labeling with anti-GFAP (red; B,E) identifies astrocytes.
Merged images (C,F) do not demonstrate EGFP expression in astrocytes in RSA59 or RSMHV2 infected mice. All images 100X.
colocalization within the myelin sheath as well. No EGFP
axonal staining or double labeling is detected after RSMHV2
infection. While some EGFP signal is observed in the gray
matter, there is no double labeling following infection with either
strain. Therefore, the RSA59, but not the RSMHV2 strain is
capable of intra-axonal transport with spread to the myelin
sheath.
RSA59Viral Antigen Axonal Spread to
Spinal Cord White Matter
In order to further confirm that RSA59 viral antigen
spreads to spinal cord white matter via axons, serial double
immunofluorescence was performed with axonal microtubule
marker Tau; dendritic microtubule markers MAP2(2a +
2b), neurofilament, and synaptophysin (presynaptic vesicle
membrane glycoprotein). As can be seen in Figure 7, viral
antigen (EGFP) colocalizes with neurons and their axonal
microtubules in the spinal cord white matter. Merged
Tau immunofluorescence images with EGFP demonstrates
colocalization in the white matter and the region of the
gray-white matter junction (Figure 7C), demonstrating that
viral antigen is present in the axons of infected neurons.
Similarly, MAP2(2a + 2b) immunofluorescence, a marker of
the somatodendritic compartments of neurons, colocalizes
with EGFP (Figures 7F,I). Note that MAP2 is also expressed
in some axons and EGFP positive axons crossing through
the gray matter from the posterior columns demonstrate
doubly labeled axons (Figure 7F). Neurofilament antibody
labeled the neuronal cell bodies and axons in the spinal cord
(Figure 7K). In the white matter of the spinal cord, there
are several examples of Neurofilament immunofluorescence
colocalizing with EGFP (Figure 7L). Anti-Synaptophysin
antibody marks presynaptic vesicles. RSA59 viral antigen
positive cells partially colocalized with synaptophysin
(Figure 7O).
Quantification of Virally Infected
Oligodendrocytes In vivo and In vitro
The statistical significance of viral strain infectivity in vivo
and in vitro was determined by examination of random
spinal cord sections or tissue culture fields in which one
hundred olig2 positive cells were counted by a blinded
investigator as described in the Materials and Methods Section.
Quantitative analysis of the relative infectivity of RSA59
(DM) and RSMHV2 (NDM) demonstrates that RSA59 strain
infects 50% of olig2 positive oligodendrocytes in white matter
(P < 0.005) and very few in gray matter. In contrast,
RSMHV2 infects less than 2% of oligodendrocytes in white
matter and none in gray matter (Figure 8A). Quantitative
analysis of the relative infectivity of RSA59 (DM) and
RSMHV2 (NDM) demonstrates that RSA59 strain infects
45% of PLP positive oligodendrocytes. In contrast, RSMHV2
infects less than 1% of oligodendrocytes (Figure 8B; P <
0.005).
Quantitative analysis of the infectivity of RSA59 (DM)
and RSMHV2 (NDM) demonstrates that both RSA59 and
RSMHV2 strains infect 50–60% of oligodendrocyte precursors
(OPC) (Figure 8C). In contrast, there is a significant difference
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FIGURE 6 | Co-localization of EGFP- and myelin (PLP) in spinal cords of mice infected with RSA59 or RSMHV2. Mice were infected with RSA59 (A–C,
100X; D–F, 200X) or RSMHV2 (G–I, 100X). EGFP fluorescence (green) identifies virus infected cells (A,D,G) while anti-PLP labeling (red) was used to detect PLP in the
myelin sheath (B,E,H). Merged images of spinal cord sections from RSA59-infected mice (C,F) demonstrate EGFP positive axons and co-localization of PLP and
EGFP in the surrounding myelin sheaths. However, no co-localization of PLP and EGFP is observed in spinal cord sections from RSMHV2-infected mice (I). The white
outline in (G) marks the location of dorsal columns.
(more than 10-fold) in the ability of RSA59 and RSMHV2
to infect differentiated oligodendrocytes (DO; P < 0.005;
Figure 8D).
DISCUSSION
Isogenic MHV strains RSA59 and RSMHV2 are both capable
of causing hepatitis, encephalitis, and meningitis, but RSMHV2
is unable to effect subsequent demyelination (Das Sarma et al.,
2008, 2009). Following viral infection, axonal damage can occur
concurrently with and independently of demyelination and direct
viral-mediated axonal damage can occur as a primary pathology,
separate from demyelination. Despite the fact that both strains
can infect neurons, there is impaired inter-neuronal spread of
the RSMHV2 strain in vivo and in vitro as well as a lack of
translocation from gray matter to white matter (Das Sarma
et al., 2009) in the spinal cord. Strain specific viral dissemination
and selective replication in CNS cells are also critical for
MHV induced neuropathology. Our studies demonstrated that
different doses of the viral strains (RSA59, 20,000 PFU vs.
RSMHV2, 100 PFU) do not affect astrocyte infection within the
brain (Das Sarma et al., 2008). The two very distinct and different
doses of viruses used are based on 50% of the LD50, where
previously it has been demonstrated that both strains replicate
at a similar rate in the brain and spinal cord and viral titers at
day 5 and day 7 post-infection are almost the same (Das Sarma
et al., 2000, 2009). Moreover, even at 100 PFUs inoculation,
RSA59 can cause demyelination although the number and size of
demyelinating plaques formed was less compared to an inoculum
of 20,000 PFUs (Das Sarma et al., 2000).
The current differential oligodendroglial tropism studies both
in vitro and in vivo suggest that direct oligodendrocyte infection
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FIGURE 7 | Immunolabeling of RSA59 infected spinal cord sections with different neuronal specific markers. Virus-infected cells (green; A,D,G,J,M) can
be seen in posterior columns and adjacent dorsal gray matter (A–F) or ventral horn region (G–O) of spinal cords from mice infected with RSA59. Cells immunolabeled
for Tau (B), Map2 (2a + 2b) (E,H), Neurofilament (K), and synaptophysin (N) are shown in red. Merged images demonstrating viral infected cells and cells with different
specific antibody labeling are shown in (C,F,I,L,O). The insets show magnified views of the co-localization of RSA59 infected cells with the neuronal cytoskeletal
markers. All magnifications are 630X.
may be a requirement for MHV to promote demyelination.
RSMHV2 infection was restricted to the gray matter whereas
Olig2 stained cells were observed in both gray and white
matter. No colocalization was observed even in the gray matter.
Furthermore, there were no examples of Olig2 nuclear/EGFP
cytoplasmic fluorescence of cells as was observed in the RSA59
infected mice. In vitro, oligodendrocyte precursors were infected
by both strains whereas differentiated oligodendrocytes were only
infected by the DM strain, suggesting that one needs to infect
the mature oligodendrocytes, cells capable of producing myelin,
in order to cause demyelination. Infection of OPCs might,
however, prevent remyelination following demyelination as the
OPCs are likely to be the cell type of choice for remyelination.
Moreover, RSA59 strain not only infected oligodendrocytes,
but also caused formation of syncytia. In contrast, RSMHV2
infected oligodendrocytes were unable to form syncytia. Taken
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FIGURE 8 | Quantification of infected oligodendrocytes in vivo and in vitro by RSA59 and RSMHV2. (A) Percentage of infected (EGFP positive)
oligodendrocytes (olig2 positive) in DM and NDM infection 6 days p.i. Ten random spinal cord sections were examined from mice infected with RSA59 (DM) or
RSMHV2 (NDM) strains. One hundred olig2 positive cells were counted and the percentage of olig2 positive cells also positive for viral antigen (EGFP) was determined
in both gray (GM) and white matter (WM). (B) Percentage of infected (EGFP positive) oligodendrocytes (PLP positive) in DM and NDM infection 6 days p.i. Ten random
spinal cord sections were examined. One hundred PLP positive cells were counted and the percentage of PLP positive cells also positive for viral antigen (EGFP) was
determined. (C) Percentage of DM and NDM infected (EGFP positive) oligodendrocyte precursors (OPC) in vitro. Cultures were infected with DM or NDM strain at a
MOI of 1 for 24 h. One hundred OPCs were counted in 10 separate random fields in tissue culture dishes and the percentage of EGFP positive OPCs was determined.
(D) Percentage of DM and NDM infected (EGFP positive) differentiated oligodendrocytes (DO) in vitro. Cultures were infected with DM or NMD strain at a MOI of 1 for
24 h. One hundred DOs were counted in 10 separate random fields in tissue culture dishes and the percentage of EGFP positive DOs was determined. Statistical
comparisons between the percentage of oligodendrocytes (OPCs or DOs) infected by RSA59 vs. RSMHV2 were made using unpaired two tailed student t-tests.
Asterisks indicate significant differences (****p < 0.001).
together, our data support direct infection of oligodendrocytes as
a potentially critical factor for viral induced demyelination.
In addition to virus being found in oligodendrocyte cell
bodies, our results show by double labeling with EGFP and
anti-PLP immunofluorescence that the RSA59 strain localizes
to axons whereas the RSMHV2 strain does not. This lack
of transport of the RSMHV2 strain to spinal cord white
matter may explain its failure to induce demyelination.
Immunofluorescence and colocalization studies with
neuronal cytoskeleton specific markers also demonstrate
that RSA59 strain colocalizes with axonal microtubules,
dendritic microtubules and neurofilament protein as well
as presynaptic vesicles (synaptophysin). The latter result
provides evidence for a mechanism by which RSA59 can spread
transynaptically to the spinal cord white matter and gain access
to oligodendrocytes and the myelin sheath. In a recent study, we
also demonstrated that RSA59 can directly infect and activate
microglia in the spinal cord white matter (Chatterjee et al.,
2013).
In the brain, viral infection of oligodendrocytes was identified
following infection with both the RSA59 and RSMHV2
(unpublished data), whereas current data in the spinal cord shows
oligodendrocyte infection only with RSA59. This differential viral
tropism between the brain and spinal cord is likely due to the
route by which virus gains access to the white matter. Mice
are infected by transcranial inoculation, a traumatic disruption
of the gray-white matter interface that permits viral particles
direct access to myelin. From the myelin sheath, viral particles
could then spread proximally to the oligodendrocyte cytoplasm.
In contrast, viral involvement of the spinal cord occurs non-
traumatically. A major mechanism of viral spread to spinal cord
white matter is through spike-mediated axonal transport (Das
Sarma et al., 2009), which may partly explain the inability of
RSMHV2 viral antigen to enter oligodendrocytes in the spinal
cord. Our results demonstrate that even though RSMHV2 virus
reaches spinal cord gray matter neurons and replicates (Das
Sarma et al., 2008), it does not spread to oligodendrocytes or
myelin. Thus, spike glycoprotein must also play a significant
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role in facilitating direct spread of virus from neurons to
oligodendrocytes.
The overall pattern of co-localization of viral antigen in
specific CNS cell types provides a logical mechanism for MHV
infection of the spinal cord. Brain neurons can be infected with
both RSA59 and RSMHV2 following intracranial inoculation.
Virions are likely unrestricted within neuronal cytoplasm and
therefore able to diffuse or be actively transported through the
axoplasm into spinal cord gray matter. From the axoplasm,
only the RSA59 virus is then capable of spreading to spinal
cord neurons and being transported anterogradely to the white
matter, or of crossing into the myelin sheath and from there,
into the oligodendrocyte cytoplasm. The lack of co-localization
with GFAP with either strain indicates that the spread of MHV
infection in the spinal cord does not involve an indirect route to
oligodendrocytes through astrocytes. The lack of viral infection
in spinal cord astrocytes is unexpected since our previous work
(Das Sarma et al., 2008) clearly showed that both RSA59 and
RSMHV2 could infect brain astrocytes in vivo. As described
above, there was a similar discrepancy in the colocalization
of EGFP in brain vs. spinal cord oligodendrocytes due to
the different routes of infection (unpublished data). Traumatic
transcranial inoculation likely provides viral access to astrocytes
due to disruption of the pia and blood/brain barrier whereas
no such disruption occurs in the spinal cord. Our results
are similar to those seen with other viral strains; direct viral
induced oligodendroglial dystrophy is a common etiology of JC
virus induced demyelination (Weiner et al., 1972; Major et al.,
1992).
Despite strong suspicions of a viral etiology, no specific
virus has been identified that is responsible for MS in humans.
Understanding the mechanisms by which known viruses effect
demyelination in an animal model has important therapeutic
implications in the treatment of human demyelinating disease.
Our experimental system is a valuable tool in this regard
and, more generally, in the elucidation of the mechanisms
of how neurotropic viral infection can directly lead to
oligodendrogliopathy in demyelination.
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